Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

Swiss drug major Novartis AG on Tuesday raised its core operating income and sales guidance for fiscal 2024 after reporting ...

Novartis NOVN-0.15%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

With their headquarters in next year’s Host City, it’s great to have Novartis, a global leader in healthcare, supporting the ...

which allows drugmakers to get their generic medicines approved for one or several—but not all—approved indications of their brand-name counterparts. Novartis disagrees with the decision and ...

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China ... Jimenez ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...